2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase EARLY_PHASE1
1
Phase 2/3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
410
Cyclophosphamide
394
Carboplatin
306
Gemcitabine
286
Nivolumab
276
Paclitaxel
274
Cisplatin
252
Radiotherapy
225
Dexamethasone
210
Bevacizumab
209
fludarabine
192
Docetaxel
187
Rituximab
183
Capecitabine
171
Oxaliplatin
158
Lenalidomide
157
Fluorouracil
152
Temozolomide
138
Cytarabine
135
Etoposide
128
Irinotecan
124
Cetuximab
123
fludarabine phosphate
120
Injections
118
venetoclax
116
Ipilimumab
115
Doxorubicin
114
Azacitidine
108
130-nm albumin-bound paclitaxel
108
Pemetrexed
107
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts